← Scroll for more →
Tevogen Bio Holdings Inc. (TVGNW)
Biological Products, (No Diagnostic Substances)
Latest Price
$0.08
Market Cap
$360,408
TTM P/E
--
Earnings Yield
--
TTM Div Yield
--
P/B Ratio
--
Price at the 2026-11-06 close. Earnings yield is trailing 12-month earnings divided by price.
Price
full chart →- 1-Year Change
- +71.46%
- 52-Week High
- $0.12
- 52-Week Low
- $0.03
Daily close, 2025-11-06 to 2026-11-06
Financials
financial statements →| Quarter ending | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Last 4 quarters |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income | $1.61M | $2.61M | $1.24M | -$195,056 | -$278,746 | -$828,923 | $11.26M | -$9.66M | -$5.88M | -$9.44M | -$10.37M | -$5.50M | -$5.73M | -$4.68M | -$5.45M | -$5.76M | -$21.61M |
| Operating cash flow | -$42,598 | -$13,861 | -$76,903 | -$397,273 | -$208,464 | -$693,711 | -$2.16M | -$2.98M | -$3.80M | -$3.05M | -$3.31M | -$3.19M | -$3.65M | -$2.18M | -$2.73M | -$3.01M | -$11.57M |
| Free cash flow | -- | -- | -$209,903 | -$397,273 | -$208,464 | -$693,711 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Chart: net income per quarter, Sep 2022 to Jun 2026. Hover over or tap a row to chart it.
Each chart: quarters ending Sep 2022 to Jun 2026. Tap a bar to see that quarter.
Net income
Last 4 quarters -$21.61M
Jun 2026 -$5.76M
$15M$0-$15M
Operating cash flow
Last 4 quarters -$11.57M
Jun 2026 -$3.01M
$0-$4M
Free cash flow
Last 4 quarters --
Jun 2026 --
$0-$800K
Capital Structure
balance sheet →- Shares Outstanding
- 4.26M
- Total Debt
- --
- Long-term Debt
- --
- Long-term Debt / Capital
- --
- Cash
- --
- Current Assets
- $2.01M
- Current Liabilities
- $6.15M
Current position as of 2026-06-30.
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FourWorld Capital Management LLC | 1.45M | $8.0M | 34.08% | -- | 2026-06-30 |
| Calamos Advisors LLC | 1.00M | -- | 23.50% | -- | 2026-06-30 |
| Parallax Volatility Advisers, L.P. | 790.9K | -- | 18.59% | -- | 2026-06-30 |
| Greenland Capital Management LP | 703.0K | -- | 16.52% | -- | 2026-06-30 |
| Polar Asset Management Partners Inc. | 700.0K | -- | 16.45% | -- | 2026-06-30 |
| MMCAP International Inc. SPC | 650.0K | -- | 15.28% | -- | 2026-06-30 |
| Linden Advisors LP | 650.0K | -- | 15.28% | -- | 2026-06-30 |
| Clear Street Group Inc. | 282.8K | -- | 6.65% | -- | 2026-06-30 |
| Aristeia Capital, L.L.C. | 245.2K | -- | 5.76% | -- | 2026-06-30 |
| Wolverine Asset Management LLC | 200.6K | -- | 4.72% | -- | 2026-06-30 |
Recent Material Events
all events →- Tevogen Inc. announced that Susan Podlogar resigned from the Board of Directors effective November 2, 2026. In response, the Board reduced its size from six to five members and appointed current director Lindee Goh to serve on the Audit Committee, also effective immediately. The company operates in the biotechnology sector.
- Tevogen Inc. entered into a First Amendment to its Loan Agreement with The Patel Family, LLP on October 27, 2026. The amendment extends the borrowing period for the unsecured line of credit from May 31, 2027, to May 31, 2029, and increases the aggregate post-amendment borrowing limit to $28.6 million. On November 2, 2026, Tevogen repaid the entire outstanding principal balance of $7.4 million plus accrued interest by issuing 1,000,000 principal shares and 23,733 interest shares at a fixed price of $7.40 per share. Additionally, the company granted CEO Ryan Saadi a restricted stock award covering 50,000,000 shares that vest only upon achieving $1.0 billion in aggregate revenue by December 31, 2031. Tevogen Inc. operates in the biotechnology industry, focusing on developing treatments for neurological disorders.